Africa’s migratory birds are threatened by changing weather patterns in the center and east of the continent that have depleted natural water systems and caused a devastating drought.

Hotter and drier conditions due to climate change make it difficult for traveling species who are losing their water sources and breeding grounds, with many now endangered or forced to alter their migration patterns entirely by settling in cooler northern areas.

Roughly 10% of Africa’s more than 2,000 bird species, including dozens of migratory birds, are threatened, with 28 species — such as the Madagascar fish eagle, the Taita falcon and hooded vultures — classed as “critically endangered.” Over one-third of them are especially vulnerable to climate change and extreme weather, an analysis by the environmental group BirdLife International said.

“Birds are being affected by climate change just like any other species,” BirdLife policy coordinator Ken Mwathe said. “Migratory birds are affected more than other groups of birds because they must keep on moving,” which makes it more likely that a site they rely on during their journey has degraded in some way.

The African-Eurasian flyway, the flight corridor for birds that travel south through the Mediterranean Sea and Sahara Desert for the winter, harbors over 2,600 sites for migrating birds. An estimated 87% of African sites are at risk from climate change, a greater proportion than in Europe or Asia, a study by the United Nations environment agency and conservation group Wetlands International found.

Africa is more vulnerable to climate change because it is less able to adapt, said Evans Mukolwe, a retired meteorologist and science director at the World Meteorological Organization.

“Poverty, biodiversity degradation, extreme weather events, lack of capital and access to new technologies” make it more difficult for the continent to protect habitats for wild species, Mukolwe said.

Hotter temperatures due to human-caused climate change and less rainfall shrink key wetland areas and water sources, which birds rely on during migratory journeys.

“Lake Chad is an example,” Mwathe said. “Before birds cross the Sahara, they stop by Lake Chad, and then move to the Northern or Southern Hemisphere. But Lake Chad has been shrinking over the years,” which compromises its ability to support birds, he said.

Parched birds mean tougher journeys, which has an impact on their ability to breed, said Paul Matiku, executive director of Nature Kenya.

Flamingoes, for example, which normally breed in Lake Natron in Tanzania are unlikely to be able to “if the migration journey is too rough,” Matiku said.

He added that “not having water in those wetlands means breeding will not take place” since flamingoes need water to create mud nests that keep their eggs away from the intense heat of dry ground.

Non-migratory birds are also struggling with the changing climate. African fish eagles, found throughout sub-Saharan Africa, are now forced to travel farther in search of food. The number of South African Cape Rockjumpers and Protea canaries is severely declining.

Bird species living in the hottest and driest areas, like in the Kalahari Desert that spans Botswana, Namibia and South Africa, are approaching their “physiological limits,” the most recent assessment by the U.N.’s expert climate panel said. It added that birds are less able to find food and are losing body mass, causing large-scale deaths for those living in extreme heat.

“Forest habitats get hotter with climate change and … dryland habitats get drier and savannah birds lack food because grass never seeds, flowers never fruit, and insects never emerge as they do when it rains,” Matiku said.

Other threats, such as the illegal wildlife trade, agriculture, the growth of urban areas and pollution are also stunting bird populations like African fish eagles and vultures, he said.

Better land management projects that help restore degraded wetlands and forests and protect areas from infrastructure, poaching or logging will help preserve the most vulnerable species, the U.N. environmental agency said.

Birds and other species would benefit from concerted efforts to improve water access and food security, especially as sea levels rise and extreme weather events are set to continue, said Amos Makarau, the Africa regional director of the U.N. weather agency.

Scientists say that curbing emissions of planet-warming gases, especially in high-emitting nations, could also limit future weather-related catastrophes.
…

Indonesia has confirmed its first monkeypox infection, detected in a person who had returned from an unidentified country with documented cases, a health ministry spokesman said Saturday.

The 27-year-old male tested positive in the capital Jakarta late Friday, Mohammad Syahril told a news conference.  

The Indonesian national, who is doing “well” and showing only mild symptoms, is self-isolating at home, said Syahril, who did not say where the patient had come from.

“We have followed up with tracing of close contacts and will check up on them,” he said, adding the government is in the process of procuring around 10,000 vaccines for monkeypox.

The health ministry is urging calm and has reassured the public that monkeypox is treatable. It has so far tested 22 suspected cases from across the country, all of which were negative.

Neighboring Singapore reported its first local case of monkeypox last month and had 15 confirmed cases as of August 5.

Elsewhere in Southeast Asia, the Philippines and Thailand also have confirmed cases.

The World Health Organization has declared a global health emergency, with more than 40,000 confirmed cases of monkeypox, including a handful of deaths, in more than 80 countries where the virus is not endemic.
…

When Stephen Nixon recently noticed a “beautiful” spotted lanternfly by his bag as he skateboarded in Brooklyn, he heeded the request of city officials. 

He stomped on it. 

“I don’t like killing things. Not many people do. I’ll catch and release cockroaches if I find them in my apartment,” Nixon said. But he said it “seems like something worse” if the insect’s population explodes. 

Kill-on-sight requests in New York City and elsewhere are a part of public campaigns to fight an invasive insect now massing and feeding on plants around much of the eastern United States. Pretty with red wing markings, the spotted lanternfly is nonetheless a nuisance and a threat — the sort of insect that inspires people to post about squishing and stomping them on social media. 

In cities, they swarm outside buildings and land on pedestrians. They excrete a sticky substance called honeydew that can collect on outdoor furniture. The sap-sucking insects also pose a danger to grapes and other agricultural crops, which is raising alarms this summer in New York state wine country. 

Across mid-Atlantic states, officials are asking people to help them track and slow the insect’s spread, even if they have to put their foot down. 

“Be vigilant,” said Chris Logue of New York’s Department of Agriculture. 

Entered country in 2014

A native of Asia, the spotted lanternfly was first identified in the United States in 2014, northwest of Philadelphia. It’s likely that insect eggs came over with a load of landscaping stones. Eight years later, there are reported infestations in 13 states, mostly on the East Coast, according to the New York State Integrated Pest Management program at Cornell University. Individual insects have been spotted in more states, with two turning up in Iowa this summer. 

The insect has been able to spread so far, so fast because it is a stealthy hitchhiker. Drivers this time of year unwittingly give lifts to adults, which look like moths, perched inside trunks, on wheel wells or on bumpers. 

“Check your vehicle,” Logue said. “What you’re really after is anything that maybe is alive, that is kind of hunkered down in there and is not going to get blown off the vehicle during the trip. Really, really important.” 

People also unknowingly transport spotted lanternfly eggs, which are laid later in the season. Females leave masses of 30 or more eggs on all sorts of surfaces, from tree trunks to patio furniture. Eggs laid on portable surfaces, like camping trailers and train cars, can hatch in the spring many miles away. 

Spotted lanternfly fighters are doing everything from applying pesticides to cutting down trees of heaven — another invasive species that is a favored host of the spotted lanternfly. But public involvement is front and center. 

In Pennsylvania, residents in quarantined counties are asked to check for the pests on dozens of items — from their vehicles to camping gear to lumber and shrubs — before heading to nonquarantined destinations. 

Be merciless

Around the East, people are being asked to report sightings to help track the spread. 

And if you see one? Show no mercy. 

“Kill it! Squash it, smash it … just get rid of it,” reads a post by Pennsylvania agricultural officials. 

New York City parks officials agree, advising: “Please squish and dispose.” 

“Join Jersey’s Stomp Team” read billboards in New Jersey showing a shoe about to stamp out an insect. 

Heide Estes did just that after seeing a spotted lanternfly on a Sunday walk in Long Branch, New Jersey, this month. 

“I came back, and I said to my partner, ‘You know, I saw a spotted lanternfly,’ ” Estes said, “and she was like, ‘Oh, I’m sure there’s more. Let’s go look.’ ” 

There were more. 

Her partner, an entomologist, put four in a plastic bottle to show co-workers on campus what they look like. They killed at least a dozen more. Many were massed on trees of heaven. 

“Clearly, the whole spot was infested,” she said. 

Nearing vineyards

Infestations in New York state had been concentrated in the metropolitan area but have spread close to the state’s wine-growing vineyards. Agricultural officials are concerned about the fate of vineyards in the Finger Lakes, the Hudson Valley and Long Island if infestations spread. U.S. Senator Chuck Schumer said Sunday that the insect could cost the state millions. 

“The spotted lanternfly sucks the sap out of the vines,” said Brian Eshenaur, an expert with the Cornell pest program. “And it makes them less hardy for the winter, so vines can be lost over the growing season.” 

Eshenaur said they’re more likely to spread into vineyards later in the season, when trees of heaven enter dormancy.

At Sheldrake Point Winery in the Finger Lakes, vineyard manager David Wiemann said workers in the rows already know to be on guard. 

“We’ve talked about how detrimental it would be to the vineyards,” Wiemann said. “So if they see one, they would let me know.”
…

A smaller dose of the monkeypox vaccine appears to still be effective and can be used to stretch the current supply by five times, the European Medicines Agency said Friday, echoing a recommendation made earlier this month by the U.S. Food and Drug Administration.

The EU drug regulator said in a statement that injecting people with one-fifth of the regular dose of the smallpox vaccine made by Bavarian Nordic appeared to produce similar levels of antibodies against monkeypox as a full dose.

The approach calls for administering Bavarian Nordic’s vaccine with an injection just under the skin rather than into deeper tissue, a practice that may stimulate a better immune response. People still need to get two doses, about four weeks apart.

The EMA said national authorities could decide, “as a temporary measure” to use smaller doses of the vaccine to protect vulnerable people during the ongoing monkeypox outbreak.

EU health commissioner Stella Kyriakides said the decision would allow the vaccination of five times as many people with the continent’s current supply.

“This ensures greater access to vaccination for citizens at risk and health care workers,” she said in a statement.

Earlier this month, the U.S. FDA authorized a similar plan to extend the country’s monkeypox vaccine stocks. The technique has previously been used to stretch supplies of vaccines during other outbreaks, including yellow fever and polio.

The unusual recommendations from both regulators acknowledge the extremely limited global supplies of the Jynneos vaccine, originally developed against smallpox. Bavarian Nordic is the only company that makes it, and it expects to have about 16 million doses available this year. On Thursday, the U.S. also announced a new agreement with a Michigan manufacturer to help speed production of 5.5 million vaccine vials recently ordered by the government.

The EMA authorized the vaccine in July based on experimental data that suggested it would work; the World Health Organization has estimated the shot is about 85% effective at preventing monkeypox.

Globally, there are more than 40,000 cases of monkeypox, of which about half are in Europe. Earlier this week, WHO chief Tedros Adhanom Ghebreyesus said there has been a 20% increase in cases reported in the last two weeks and that nearly all infections have been reported in men who are gay, bisexual or have sex with other men.

Tedros said WHO was in talks with vaccine manufacturers and countries to see if any might be willing to share doses. Africa has reported the highest number of suspected monkeypox deaths and although the disease has been endemic in parts of central and west Africa for decades, it has only a small supply of vaccines being used as part of a research study.

About 98% of monkeypox cases beyond Africa have been reported in men who are gay, bisexual or have sex with other men. WHO said there is no sign of sustained transmission beyond men who have sex with men, although a small number of women and children have also been sickened by the disease.

Monkeypox spreads when people have close, physical contact with an infected person’s lesions, their clothing or bed sheets. Most people recover without needing treatment, but the lesions can be extremely painful and more severe cases can result in complications including brain inflammation and death.

In the U.K., which at one point had the biggest outbreak outside Africa, officials said earlier this week they have seen signs the outbreak is slowing down.
…

The World Health Organization says clinical evidence shows two monoclonal antibody treatments are effective at saving the lives of many people stricken with the deadly Ebola virus.

The action follows a systematic review and analysis of randomized clinical trials of therapeutics for the disease.

WHO Team Lead for Clinical Care Janet Diaz says the evidence underpinning the recommendations comes from two clinical trials. The largest was done in the Democratic Republic of Congo in 2018 and 2019.

She says the trials were conducted during Ebola outbreaks, demonstrating quality control trials can be done even under the most difficult circumstances.

“The evidence synthesis that informs this guideline shows that mAb114 and Regeneron-EB3 reduced mortality. The relative risk reduction was about 60 percent…Between 230 to 400 lives saved per 1,000 patients. Translate that into the number needed to treat, you treat two to four patients, and you save one life.”

Ebola hemorrhagic fever is spread through blood or body fluids of a person who is sick with or has died of the disease. The worst Ebola outbreak occurred in West Africa between 2014 and 2016. Of the nearly 29,000 reported cases, more than 11,300 people died.

Diaz calls the development of monoclonal antibody therapeutics a very important advancement. However, she notes the drug itself is not the only solution. She says it must be given in a comprehensive, clinical setting along with other treatments.

“That includes early diagnosis so that treatments can be given as soon as possible and also the implementation of appropriate infection prevention and control to stop transmission…and treatment of co-infections and access to nutrition, psycho-social support, and, of course, access to care after discharge.”

Diaz says the two recommended therapeutics have shown clear benefits for people of all ages. She says they can be used on all patients confirmed positive for Ebola virus disease. That, she says, includes older people, pregnant and breastfeeding women, children, and babies born to mothers with confirmed Ebola within the first seven days after birth.
…

A group of World Health Organization experts is recommending COVID-19 booster shots for people at the highest risk of severe illness and death. The Strategic Advisory Group of Experts on Immunization or SAGE, which met in extraordinary session August 11, issued its updated guidance Thursday.

SAGE recommends continued use of the two-dose mRNA COVID-19 vaccines. Since the vaccines’ efficacy wanes after several months, however, the group of experts advises a booster shot for everyone, beginning with those at highest risk.

This is the first time SAGE has updated its guidance on the administration of a second booster shot. Its recommendations are based on increasing evidence on the benefits of a second booster dose of COVID-19 vaccines for select groups of people.

SAGE chairman Alejandro Cravioto said the group recommends a second booster shot for people older than 55 who are considered at highest risk of developing severe disease and in need of hospitalization. He said SAGE does not advocate a second booster for the general public, for adults who are generally healthy and do not suffer from severe immunodeficiency.

“We also include persons with moderate and severe immuno-compromising conditions from, say, 6 months and above,” Cravioto said. “And that includes the children and adults with co-morbidities at higher risk of severe disease. We also include pregnant women and health workers.”

SAGE recommends a second booster be given four to six months after the administration of the first. It says healthy children and adolescents remain at low risk of severe disease from COVID-19, so there currently is no recommendation for youth groups to be vaccinated.

Cravioto, however, said SAGE has made interim recommendations for the use of Pfizer and Moderna vaccines in relation to their use in children.

“In the case of both vaccines, children from 6 months to 17 years with co-morbidities should be vaccinated to avoid a higher risk in these groups of severe disease. … This includes, of course, children with Down syndrome, who we know are at the highest risk of dying of COVID if they get infected.”

The group of experts notes the recommendations are based on the current available data. They say it is not a projection into the future but relates specifically to the omicron variant of the coronavirus. It says the guidance is likely to change depending on how the pandemic evolves and new variants circulate.
…

The White House announced Thursday it will make an additional 1.8 million doses of monkeypox vaccine available for distribution beginning next week.

At a news conference, White House national monkeypox response coordinator Bob Fenton said the additional doses will be available for U.S. jurisdictions to order starting Monday, through the Department of Health and Human Services (HHS).

U.S. Centers for Disease Control and Prevention Director Rochelle Walensky and HHS Secretary Xavier Becerra also took part in the news briefing.

Fenton said in the less than 10 days since the U.S. Food and Drug Administration and the CDC authorized the Jynneos vaccine for emergency use against monkeypox in individuals 18 years of age and older, HHS has delivered nearly 1 million doses to U.S. states and cities, making it the largest program of its kind for monkeypox vaccine in the world.

Fenton said the additional doses are part of the National Monkeypox Response Team’s plan to address the viral disease’s outbreak in the United States and mitigate its spread.

He said HHS has been working on launching a pilot program that will provide up to 50,000 doses from the national stockpile to be made available for events that will have high attendance of gay and bisexual men.

While monkeypox is not classified as a sexually transmitted infection, or STI, it has been found to be disproportionally affecting men who have sex with men. The disease can spread through close or intimate physical contact such as hugging, kissing and sex. It can also be transmitted by touching infected items such as clothing, bedding or towels.

Fenton said the Biden administration has also significantly increased availability and convenience of monkeypox tests, expanding capacity from 6,000 tests per week to 80,000 tests per week.

Some information for this report was provided by The Associated Press and Reuters.
…

Today’s sharks have nothing on their ancient cousins. A giant shark that roamed the oceans millions of years ago could have devoured a creature the size of a killer whale in just five bites, new research suggests.

For their study published Wednesday, researchers used fossil evidence to create a 3D model of the megalodon — one of the biggest predatory fish of all time — and find clues about its life.

At around 16 meters from nose to tail, the megalodon was bigger than a school bus, according to the study in the journal Science Advances. That’s about two to three times the size of today’s great white shark. The megalodon’s gaping jaw allowed it to feed on other big creatures. Once it filled its massive stomach, it could roam the oceans for months at a time, the researchers suggest.

The megalodon was a strong swimmer, too: Its average cruising speed was faster than sharks today and it could have migrated across multiple oceans with ease, they calculated.

“It would be a superpredator just dominating its ecosystem,” said co-author John Hutchinson, who studies the evolution of animal movement at England’s Royal Veterinary College. “There is nothing really matching it.

It’s been tough for scientists to get a clear picture of the megalodon, said study author Catalina Pimiento, a paleobiologist with the University of Zurich and Swansea University in Wales.

The skeleton is made of soft cartilage that doesn’t fossilize well, Pimiento said. So the scientists used what few fossils are available, including a rare collection of vertebrae that’s been at a Belgium museum since the 1860s.

Researchers also brought in a jaw’s worth of megalodon teeth, each as big as a human fist, Hutchinson said. Scans of modern great white sharks helped flesh out the rest.

Based on their digital creation, researchers calculated that the megalodon would have weighed around 70 tons, or as much as 10 elephants.

Even other high-level predators may have been lunch meat for the megalodon, which could open its jaw to almost 2 meters wide, Pimiento said.

Megalodons lived an estimated 23 million to 2.6 million years ago.

Since megalodon fossils are rare, these kinds of models require a “leap of imagination,” said Michael Gottfried, a paleontologist at Michigan State University who was not involved in the study. But he said the study’s findings are reasonable based on what is known about the giant shark. 
…

A federal judge in Cleveland awarded $650 million in damages Wednesday to two Ohio counties that won a landmark lawsuit against national pharmacy chains CVS, Walgreens and Walmart, claiming the way they distributed opioids to customers caused severe harm to communities and created a public nuisance.

U.S. District Judge Dan Polster said in the ruling that the money will be used to abate a continuing opioid crisis in Lake and Trumbull counties, outside Cleveland. Attorneys for the counties put the total price tag at $3.3 billion for the damage done to the counties.

Lake County is to receive $306 million over 15 years. Trumbull County is to receive $344 million over the same period. Polster ordered the companies to immediately pay nearly $87 million to cover the first two years of the abatement plan.

In his ruling, Polster admonished the three companies, saying they “squandered the opportunity to present a meaningful plan to abate the nuisance” after a trial that considered what damages they might owe.

CVS, Walmart and Walgreens said they will appeal the ruling. It is unclear whether the companies will have to immediately pay the nearly $87 million during their appeals.

Trumbull County Commissioner Frank Fuda praised the award in a statement, saying “the harms caused by this devastating epidemic” can now be addressed.

Lake County Commissioner John Hamercheck said in a statement: “Today marks the start of a new day in our fight to end the opioid epidemic.”

A jury returned a verdict in November in favor of the counties after a six-week trial. It was then left to Polster to decide how much the counties should receive from the three pharmacy companies. He heard testimony in May to determine damages.

The counties convinced the jury that the pharmacies played an outsized role in creating a public nuisance in the way they dispensed pain medication into their communities.

It was the first time pharmacy companies completed a trial to defend themselves in a drug crisis that has killed a half-million Americans since 1999.

Attorneys for the pharmacy chains maintained they had policies to stem the flow of pills when their pharmacists had concerns and would notify authorities about suspicious orders from doctors. They also said it was doctors who controlled how many pills were prescribed for legitimate medical needs, not their pharmacies.

Walmart issued a statement Wednesday saying the counties’ attorneys “sued Walmart in search of deep pockets, and this judgment follows a trial that was engineered to favor the plaintiffs’ attorneys and was riddled with remarkable legal and factual mistakes.”

Walgreens spokesperson Fraser Engerman said, “The facts and the law did not support the jury verdict last fall, and they do not support the court’s decision now.

“The court committed significant legal errors in allowing the case to go before a jury on a flawed legal theory that is inconsistent with Ohio law and compounded those errors in reaching its ruling regarding damages.”

CVS spokesperson Michael DeAngelis said, “We strongly disagree with the court’s decision regarding the counties’ abatement plan, as well as last fall’s underlying verdict.”

CVS is based in Rhode Island, Walgreens in Illinois and Walmart in Arkansas.

Two chains — Rite Aid and Giant Eagle — settled lawsuits with the counties before trial. The amounts they paid have not been disclosed publicly.

Mark Lanier, an attorney for the counties, said during the trial that the pharmacies were attempting to blame everyone but themselves.

The opioid crisis has overwhelmed courts, social services agencies and law enforcement in Ohio’s blue-collar corner east of Cleveland, leaving behind heartbroken families and babies born to addicted mothers, Lanier told jurors.

Roughly 80 million prescription painkillers were dispensed in Trumbull County alone between 2012 and 2016 — equivalent to 400 for every resident. In Lake County, 61 million pills were distributed during that period.

The rise in physicians prescribing pain medications such as oxycodone and hydrocodone came as medical groups began recognizing that patients have the right to be treated for pain, Kaspar Stoffelmayr, an attorney for Walgreens, said at the opening of the trial.

The problem, he said, was “pharmaceutical manufacturers tricked doctors into writing way too many pills.”

The counties said pharmacies should be the last line of defense to prevent the pills from getting into the wrong hands.

The trial before Polster was part of a broader constellation of about 3,000 federal opioid lawsuits consolidated under his supervision. Other cases are moving ahead in state courts.

Kevin Roy, chief public policy officer at Shatterproof, an organization that advocates for solutions to addiction, said in November that the verdict could lead pharmacies to follow the path of major distribution companies and some drugmakers that have reached nationwide settlements of opioid cases worth billions. So far, no pharmacy has reached a nationwide settlement.

Also on Wednesday, attorneys general from numerous states announced they had reached an agreement with Endo International to pay as much as $450 million over 10 years to settle allegations the company used deceptive marketing practices “that downplayed the risk of addiction and overstated the benefits” of opioids it produced.

Based in Ireland, Endo’s U.S. headquarters are in Malvern, Pennsylvania. The company did not respond Wednesday to telephone and email requests for comment.

The agreement calls for the $450 million to be divided among participating states and communities. It also calls for Endo to put opioid-related documents online for public viewing and pay $2.75 million in expenses to publicly archive those documents.

Endo can never again market opioids, according to the agreement.

The company filed for Chapter 11 bankruptcy protection Tuesday night.

Endo produces generic opioids and name brands such as Percocet and Endocet. The company’s Opana ER opioid was withdrawn from the market in 2017. The attorneys general say Endo “falsely promoted the benefits” of Opana ER’s “so-called abuse deterrent formulation.” The attorneys general said the formulation did not deter abuse of the drug and led to deadly outbreaks of hepatitis and HIV resulting from people injecting the drug.
…

Studies are underway to see whether genetic changes in the monkeypox virus are driving the rapid spread of the disease, the World Health Organization told AFP on Wednesday.

The two distinct clades, or variants, of the virus were called the Congo Basin (Central African) and West African clades, after the two regions where they are each endemic.

On Friday, the WHO renamed the groupings as clade I and clade II respectively, to avoid geographic stigmatization.

It also announced that clade II had two sub-clades, IIa and IIb, with viruses within the latter identified as being behind the current global outbreak.

On Wednesday, the U.N. health agency specified that clades IIa and IIb are related and share a recent common ancestor, therefore IIb is not an offshoot of IIa.

Research into mutations

Clade IIb contains viruses collected in the 1970s, and from 2017 onward.

“Looking through the genome, indeed there are a few genetic differences between the viruses from the current outbreak and the older clade IIb viruses,” the WHO told AFP.

“However, nothing is known about the significance of these genetic changes, and research is ongoing to establish the effects (if any) of these mutations on transmission and disease severity.

“It is still early on in both the outbreak and laboratory studies to tell if the rise in infections could be driven by the observed genotypic changes in the virus or are due to host (human) factors.”

There is also no information yet on what the mutations mean in terms of how the virus interacts with the human immune response.

A surge in monkeypox infections has been reported since early May outside the endemic African countries.

The WHO declared the situation an international public health emergency on July 23.

More than 35,000 cases in 92 countries, and 12 deaths, have now been reported to the WHO.

Almost all new cases are being reported from Europe and the Americas.

Experts have been studying samples from cases.

“The diversity between the viruses responsible for the current outbreak is minimal, and there is no obvious genotypic differences between the viruses from the non-endemic countries,” the WHO said.

Renaming monkeypox could take months

Meanwhile the WHO said its drive to rename monkeypox could take “a number of months.”

The organization has for weeks voiced concern about the name, with experts concerned that it is misleading.

Monkeypox received its name because the virus was originally identified in monkeys kept for research in Denmark in 1958.

However, the disease is found most frequently in rodents, and the current outbreak is being spread through human-to-human close contact.

The WHO has called for help from the public in coming up with a new name, with a dedicated website where anyone can make suggestions.

“We will update the public by the end of the year,” the WHO said.
…

The head of the top U.S. public health agency on Wednesday announced a shake-up of the organization, intended to make it more nimble.

The planned changes at the Centers for Disease Control and Prevention — CDC leaders call it a “reset”— come amid ongoing criticism of the agency’s response to COVID-19, monkeypox and other public health threats. The changes include internal staffing moves and steps to speed up data releases.

The CDC’s director, Dr. Rochelle Walensky, told the agency’s staff about the changes on Wednesday. It’s a CDC initiative, and was not directed by the White House or other administration officials, she said.

“I feel like it’s my my responsibility to lead this agency to a better place after a really challenging three years,” Walensky told The Associated Press.

The CDC, with a $12 billion budget and more than 11,000 employees, is an Atlanta-based federal agency charged with protecting Americans from disease outbreaks and other public health threats. It’s customary for each CDC director to do some reorganizing, but Walensky’s action comes amid a wider demand for change.

The agency has long been criticized as too ponderous, focusing on collection and analysis of data but not acting quickly against new health threats. But public unhappiness with the agency grew dramatically during the COVID-19 pandemic. Experts said the CDC was slow to recognize how much virus was entering the U.S. from Europe, to recommend people wear masks, to say the virus can spread through the air, and to ramp up systematic testing for new variants.

“We saw during COVID that CDC’s structures, frankly, weren’t designed to take in information, digest it and disseminate it to the public at the speed necessary,” said Jason Schwartz, a health policy researcher at the Yale School of Public Health.

Walensky, who became director in January 2021, has long said the agency has to move faster and communicate better, but stumbles have continued during her tenure.

In April, she called for an in-depth review of the agency, which resulted in the announced changes. Her reorganization proposal must be approved by the Department of Health and Human Services secretary. CDC officials say they hope to have a full package of changes finalized, approved, and underway by early next year.

Some changes still are being formulated, but steps announced Wednesday include:

—Increasing use of preprint scientific reports to get out actionable data, instead of waiting for research to go through peer review and publication by the CDC journal Morbidity and Mortality Weekly Report.

—Restructuring the agency’s communications office and further revamping CDC websites to make the agency’s guidance for the public more clear and easier to find.

—Altering the length of time agency leaders are devoted to outbreak responses to a minimum of six months — an effort to address a turnover problem that at times caused knowledge gaps and affected the agency’s communications.

—Creation of a new executive council to help Walensky set strategy and priorities.

—Appointing Mary Wakefield as senior counselor to implement the changes. Wakefield headed the Health Resources and Services Administration during the Obama administration and also served as the No. 2 administrator at HHS. Wakefield, 68, started Monday.

—Altering the agency’s organization chart to undo some changes made during the Trump administration.

—Establishing an office of intergovernmental affairs to smooth partnerships with other agencies, as well as a higher-level office on health equity.

Walensky also said she intends to “get rid of some of the reporting layers that exist, and I’d like to work to break down some of the silos.” She did not say exactly what that may entail, but emphasized that the overall changes are less about redrawing the organization chart than rethinking how the CDC does business and motivates staff.

“This will not be simply moving boxes” on the organization chart, she said.

Schwartz said flaws in the federal response go beyond the CDC, because the White House and other agencies were heavily involved.

A CDC reorganization is a positive step but “I hope it’s not the end of the story,” Schwartz said. He would like to see “a broader accounting” of how the federal government handles health crises.
…

Despite a nationwide vaccination campaign that started in May, Malawi is struggling to contain a cholera outbreak that has infected more than 1,073 people and caused 44 deaths. 

The figures from the Malawi Ministry of Health, updated as of Aug. 16, 2022, are triple the numbers recorded when the vaccination campaign was launched three months ago. 

The report also says the outbreak has spread to 10 districts from eight in May. The hardest hit districts include Blantyre with 489 cases, Neno with 128 cases, and Nsanje with 289 cases.  

George Mbotwa, spokesperson for a health office in Nsanje district, which borders Mozambique south of Malawi, said continued incidents of cholera in the district are largely because of movements of people between the two countries. 

“What is worrisome is that we have now continued to record the cases when by now we would have contained the situation,” he said. “It’s because some of these cases we are sharing with Mozambique. So, the cases will be coming from Mozambique and then reporting to health facilities in Nsanje, then being recorded as Nsanje cases.”

Mbotwa said the situation is slowly improving, after officials on the Mozambican side agreed during recent discussions to set up cholera treatment sites on their side of the border.  

“The Mozambican side by then didn’t have cholera treatment sites, and now they have them there, so people are able to report the cases right there, unlike coming with cases to Malawi,” he said. 

Cholera is an acute diarrheal infection caused by ingesting food or water contaminated with bacteria. The disease affects both children and adults, and if untreated, it can kill within hours.  

Penjani Chunda, environmental health officer in Blantyre, said although Blantyre is largely an urban area, cholera cases are on the rise because most people fetch water from unprotected sources like rivers and streams. 

“In most parts of Blantyre, we don’t have portable water sources,” he said. “It might be like an urban setup, but it has no portable water sources, and we have got dry taps in some of the areas and [water] kiosks are not working at all.”  

The spokesperson for the Health Ministry, Adrian Chikumbe, said health authorities are currently distributing chlorine for water treatment, and providing public education on good hygiene.  

Chikumbe also hopes the second phase of the national oral cholera vaccination campaign, which is expected to start soon in the most-hit districts, will help contain the situation.     

 
…

China’s dominance in global sector creates supply chain and national security concerns, says US solar manufacturer
…

NASA’s gigantic Space Launch System moon rocket, topped with an uncrewed astronaut capsule, is set to begin an hourslong crawl to its launchpad Tuesday night ahead of the behemoth’s debut test flight later this month. 

The 98-meter-tall rocket is scheduled to embark on its first mission to space — without any humans — on August 29. It will be a crucial, long-delayed demonstration trip to the moon in NASA’s Artemis program, the United States’ multibillion-dollar effort to return humans to the lunar surface as practice for future missions to Mars. 

The Space Launch System, whose development in the past decade has been led by Boeing, is scheduled to emerge from its assembly building at NASA’s Kennedy Space Center in Florida around 9 p.m. EDT on Tuesday (0100 GMT on Wednesday) and begin the 6-km-long trek to its launchpad. Moving less than 1.6 km per hour, the rollout takes roughly 11 hours. 

Sitting atop the rocket is NASA’s Orion astronaut capsule, a pod built by Lockheed Martin Corp LMT.N. It is designed to separate from the rocket in space, ferry humans toward the moon’s vicinity and rendezvous with a separate spacecraft that will take astronauts down to the lunar surface. 

But for the August 29 mission, called Artemis 1, the Orion capsule will launch atop the Space Launch System without any humans and orbit around the moon before returning to Earth for an ocean splashdown 42 days later. 

If bad launch weather or a minor technical issue triggers a delay from August 29, the National Aeronautics and Space Administration has backup launch dates on September 2 and September 5. 

 
…

A measles outbreak in Zimbabwe has killed at least 157 children, with more than 2,000 infections reported across the country, the government said Tuesday.

Cases have been growing rapidly in the southern African nation since authorities said the first infection was logged earlier this month, with reported deaths almost doubling in less than a week.

“As of 15 August, the cumulative figure across the country has risen to 2,056 cases and 157 deaths,” Information Minister Monica Mutsvangwa said, briefing journalists after a weekly Cabinet meeting.

Mutsvangwa said the government was going to step up vaccinations and has invoked special legislation allowing it to draw money from the national disaster fund “to deal with the emergency.”

She said the government was to engage with traditional and faith leaders to garner their support with the vaccination campaign, adding most victims were not vaccinated.

The health ministry has previously blamed the outbreak on church sect gatherings.

The measles virus attacks mainly children with the most serious complications including blindness, brain swelling, diarrhea and severe respiratory infections.

Its symptoms are a red rash that appears first on the face and spreads to the rest of the body. Once very common it can now be prevented with a vaccine.

In April, the World Health Organization (WHO) said Africa was facing an explosion of preventable diseases due to delays in vaccinating children, with measles cases jumping 400%.
…

New York health officials announced in July that an unvaccinated adult man from Rockland County had been diagnosed with polio—the first case of the life-threatening disease in the United States since 2013. The virus that causes polio was later detected in New York City wastewater, and city and state health officials now say the virus is probably circulating in the city.

The virus identified in New York is a vaccine-derived poliovirus. Wild polioviruses were eliminated from most of the world and now circulate only in Afghanistan and Pakistan.

But vaccine-derived viruses, which emerge when the weakened viruses in the oral polio vaccine mutate and spread in unvaccinated populations, still occasionally cause outbreaks.

VOA spoke with three polio experts about vaccine-derived polioviruses and the oral polio vaccine. Here’s what you need to know.

What are vaccine-derived polioviruses?

Vaccine-derived polioviruses are related to the active viruses in the oral polio vaccine (OPV).

OPV works by infecting cells in the gut with weakened polioviruses, allowing the body to safely develop immunity to polio without the risk of paralysis posed by the real disease.

“[The weakened viruses] would still infect you. They would still replicate in your gut. You will develop a lifelong immunity, but you will not get paralyzed,” said virologist Konstantin Chumakov, a Global Virus Network Center of Excellence director and an adjunct professor at The George Washington University.

“But the [vaccine-derived] virus will still be able to transmit [from person to person],” Chumakov added. “It was considered a big advantage of the vaccine, because basically, you can immunize several kids with one dose.”

This transmission becomes problematic in communities with low vaccination rates. If the virus can spread for a long time, it has many chances to mutate and revert to a dangerous paralytic form.

Why is the oral polio vaccine (OPV) used?

Although OPV is linked to vaccine-derived polioviruses, it also has a number of advantages over the inactivated polio vaccine (IPV) — the injected vaccine — which is still used in most of the world.

People who receive OPV cannot be “silent spreaders.” After developing an immune response to the vaccine, they are immune to polio for life. Polioviruses cannot replicate in their gut and infect others.

In contrast, IPV protects against paralysis, but does not prevent the virus from replicating in the gut. People who receive IPV can spread polio, even though they won’t get sick from it.

“In populations where you want to stop the spread, that ‘gut immunity’ that OPV confers is essential,” said Captain Derek Ehrhardt, a polio incident manager at the Centers for Disease Control and Prevention (CDC). “If you have just IPV, it’s possible that the child will be protected, but they could still spread [paralytic polio] to their neighbor, their brother, their sister, whomever.”

This made OPV instrumental in the eradication of wild polio from most of the world, including in countries such as the United States that now use IPV exclusively.

OPV also has other advantages.

“We work with oral polio vaccine because it is low cost,” said Richter Razafindratsimandresy, head of the National Reference Laboratory for Poliomyelitis at the Institut Pasteur de Madagascar. “And it is easy to administer, because it is oral — they don’t need to inject the children, and it is not a problem for the parents to accept.”

If OPV prevents silent spread, why are the U.S. and other nations using only IPV?

After the United States and other wealthy countries eliminated wild polio, they stopped using OPV because it carries the risk of creating vaccine-derived polioviruses in undervaccinated communities, and because it has a slight risk of causing paralysis. This happens between roughly two and four times per million births, according to the Global Polio Eradication Initiative (GPEI). Because there are so few cases in the U.S., thanks to the very successful campaigns with OPV, that risk is now seen as unacceptable.

The U.S. and other wealthy countries have robust health care systems and can effectively acquire the more expensive IPV and get it into every arm. So, using IPV means the well-vaccinated populations in these countries are well-protected from paralysis from polio, despite being less protected against catching and spreading polioviruses.

How do vaccine-derived poliovirus cause outbreaks?

Countries with weak vaccination systems are more likely to experience outbreaks of vaccine-derived poliovirus. That’s happened several times in Madagascar, Razafindratsimandresy said.

“[The virus] is not from another country. Because in Madagascar, we have … immunization coverage [that] is very, very low,” he said.

Imported vaccine-derived polioviruses can also cause outbreaks in countries with high vaccination rates, especially if IPV is used instead of OPV.

“Basically, it can transmit from person to person to person without causing any symptoms, because everybody is protected from paralysis,” said Chumakov. “But at some point, the virus can hit an unvaccinated person or a person with immune deficiency, and then it can paralyze this person. And this is exactly what happened in New York.”

Is OPV safe?

“Our vaccines are safe and effective,” said Ehrhardt. “We need to vaccinate our under- and unimmunized children to stop the ongoing spread of these viruses.”

Chumakov said that developing better versions of OPV could reduce risks while also keeping the gut immunity provided by OPV, which he said is important for preventing silent spread. He was previously involved in a GPEI effort to develop a safer oral vaccine for Type 2 polioviruses. Clinical trial data suggest the novel OPV is less likely to revert to a dangerous form.

While the future may bring improved vaccines, vaccinating as many children as possible with existing OPV remains a priority in much of the world.

According to the CDC, global polio vaccination coverage sunk to 81% in 2021, the lowest in a decade. This was largely due to the COVID-19 pandemic, but not all countries have enough resources for vaccination campaigns even in normal times.

Razafindratsimandresy said that even though Madagascar aims to vaccinate all children with OPV, the country doesn’t have enough personnel and often runs out of vaccine.

“These immunity gaps must be closed for us to stop these diseases,” Ehrhardt said. “If you have polio anywhere, then children everywhere are still at risk.”

 
…